JAMES W. JACOBBERGER, PhD
Associate Director for Shared Resources
BS– Microbiology, University of Nebraska, 1976
PhD– Microbiology and Immunology, University of Rochester, 1983
Post-doctoral fellowship–Experimental Pathology, University of Colorado Health Sciences Center, 1983-85
I am interested in cell biology, cancer cell biology, oncogenesis, "biomarkers", and mathematical modeling of cell process regulation. Early work in the lab focused on cell immortalization through expression of SV40 large T antigen and development of cytometric methods to analyze the cell cycle. Our present interests focus on analysis of cell signaling and the cell cycle by cell-based methodology, and mathematical modeling of the cell cycle and cell signaling. The latter is in collaboration with Sree Sreenath (Computer Sciences and Electrical Engineering) and Tom Radivoyevitch (Epidemiology and Biostatistics).
We have two main enterprises in the lab: "multi-variate cell cycle analysis and modeling" and "measurement and analysis of cell signaling as a leukemia biomarker". There is a single overarching goal – to test the following set of ideas within the context of human disease: (1) multi-variate cytometric data, measuring key process-related epitopes, resolve to kinetic profiles of programmed gene expression, and (2) a series of bivariate views or a single N-dimensional view of these profiles produce quantifiable/ classifiable discrete cell states that monitor cell processes (e.g., mitosis).
The long range goal is to create an analytical system, preferably within a clinical pathology or observational basic cell biology modes of investigation, in which the measurements are interactively interrogated by the investigator and a computer program with mathematical models of cell biochemistry and integrated systems simulations running underneath.
Cell cycle related
Darzynkiewicz Z, Crissman H, Jacobberger JW (2004) Cytometry of the cell cycle: Cycling through history. Cytometry Part A 58A: 21-32.
Frisa PS, Jacobberger JW (2010) Cytometry of chromatin bound Mcm6 and PCNA identifies two states in G1 that are separated functionally by the G1 restriction point. Bmc Cell Biology 11: 26.
Frisa PS, Jacobberger JW (2009) Cell Cycle-Related Cyclin B1 Quantification. Plos One 4: e7064.
Soni DV, Sramkoski RM, Lam M, Stefan T, Jacobberger JW (2008) Cyclin B1 is rate limiting but not essential for mitotic entry and progression in mammalian somatic cells. Cell Cycle 7: 1285-1300.
Jacobberger JW, Frisa PS, Sramkoski M, Stefan T, Shults KE, et al. (2008) A new biomarker for mitotic cells. Cytometry Part A 73A: 5-15.
Kunos CA, Radivoyevitch T, Pink J, Chiu SM, Stefan T, et al. (2010) Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res 174: 574-581.
Hastak K, Paul RK, Agarwal MK, Thakur VS, Amin ARMR, et al. (2008) DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation. Proceedings of the National Academy of Sciences of the United States of America 105: 6314-6319.
Mailankot M, Smith D, Howell S, Wang B, Jacobberger JW, et al. (2008) Cell Cycle Arrest by Kynurenine in Lens Epithelial Cells. Investigative Ophthalmology & Visual Science 49: 5466-5475.
Jacobberger JW (2006) Increasing the power of cytometry. Nature Methods 3: 343-344.
van Boxel-Dezaire AH, Zula JA, Xu Y, Ransohoff RM, Jacobberger JW, et al. (2010) Major Differences in the Responses of Primary Human Leukocyte Subsets to IFN-β J Immunol.
Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, et al. (2005) Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry Part A 67A: 4-17.
Jacobberger JW, Sramkoski RM, Frisa PS, Ye PP, Gottlieb MA, et al. (2003) Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity. Cytometry Part A 54A: 75-88.
Barr PM, Lazarus HM, Cooper BW, Schluchter MD, Panneerselvam A, et al. (2009) Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. American Journal of Hematology 84: 484-487.
Dowlati A, Lazarus HM, Hartman P, Jacobberger JW, Whitacre C, et al. (2003) Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies. Clinical Cancer Research 9: 5929-5935.